Why are equinocandins (antifungal drugs including caspofungin, micafungin, and anidulafungin) named as such?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Etymology of Echinocandins

Echinocandins are named after their structural origin from the fungal metabolite echinocandin B, which was first isolated from Aspergillus nidulans var. echinulatus, with "echino-" referring to the spiny or rough appearance of the fungal colony and "-candin" denoting the candida-active properties of these compounds. 1

Chemical Structure and Nomenclature

The echinocandins represent a class of semisynthetic amphiphilic lipopeptides composed of a cyclic hexapeptide core linked to a variably configured N-acyl side chain 1. This distinctive chemical structure forms the basis for the class name, as all three currently available agents (caspofungin, micafungin, and anidulafungin) share this fundamental molecular architecture 2, 3.

Historical Development

The original natural product echinocandin B was discovered as a fermentation product from fungal sources, and subsequent medicinal chemistry efforts led to the development of the three semisynthetic derivatives now used clinically 3, 4. The name reflects both:

  • The source organism's morphological characteristics (the spiny or "echino-" appearance of the fungal colony from which the parent compound was isolated) 3
  • The antifungal activity against Candida species (the "-candin" suffix highlighting the primary therapeutic target) 4, 5

Mechanism and Class Identity

The echinocandins act by noncompetitive inhibition of β-(1,3)-D-glucan synthase, an enzyme involved in the biosynthesis of β-(1,3)-D-glucan, which is a component specific to the cell wall of many fungi 1, 3. This unique mechanism of action, targeting fungal cell wall synthesis rather than membrane integrity like polyenes or ergosterol synthesis like azoles, further distinguishes this class and justifies its separate nomenclature 1.

The class name effectively communicates both the natural product origin and the primary clinical application against candidal infections, though these agents also demonstrate fungistatic activity against Aspergillus species 3, 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Echinocandins in the management of invasive fungal infections, part 1.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006

Research

The echinocandins.

Pharmacotherapy, 2007

Research

Echinocandins: the newest class of antifungals.

The Annals of pharmacotherapy, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.